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Alzheimertate levels of beta amyloid peptides (Aβ) in brain are considered an initial step in
the amyloid cascade hypothesis of Alzheimer's disease. Aβ is a product of the secretase cleavage of amyloid
precursor protein (APP). There is evidence that the membrane lipid environment may modulate secretase
activity and alters its function. Cleavage of APP strongly depends on membrane properties. Since Aβ perturbs
cell membrane ﬂuidity, the cell membrane may be the location where the neurotoxic cascade of Aβ is
initiated. Therefore, we tested effects of oligomeric Aβ on membrane ﬂuidity of whole living cells, the impact
of exogenous and cellular Aβ on the processing of APP and the role of GM-1 ganglioside. We present evidence
that oligoAβ(1–40) stimulates the amyloidogenic processing of APP by reducing membrane ﬂuidity and
complexing with GM-1 ganglioside. This dynamic action of Aβ may start a vicious circle, where endogenous
Aβ stimulates its own production. Based on our novel ﬁndings, we propose that oligoAβ(1–40) accelerates the
proteolytic cleavage of APP by decreasing membrane ﬂuidity.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most common neurodegenerative
disorder. A neuropathological hallmark of AD is amyloid plaques [1],
which contain beta-amyloid peptides (Aβ). Amphipathic Aβ tends
towards self-aggregation and accumulation, which initiates a cascade
that triggers complex pathological reactions eventually leading to
neuronal dysfunction and cell death [2–4]. Aβ aggregation is a
concentration-dependent phenomenon, which is initiated via a
seeded polymerization reaction [5]. Monomeric Aβ initially forms
poorly characterized nuclei that assemble into larger aggregates. The
nucleation of Aβ is followed by oligomer and protoﬁbril formation,
which ultimately leads to insoluble amyloid ﬁbril assembly [3].
Current research suggests that oligomeric forms of Aβ may play a
major role in AD pathophysiology [3, 4]. Soluble amyloid oligomers
(oligoAβ) bind speciﬁcally to neurons, disrupt dendritic spines [6] and
inhibit hippocampal long-term potentiation in vivo [7].
Most Aβ is composed of 38–43 amino acid residues, all deriving
from the transmembrane amyloid precursor protein (APP) after the+49 69 79829374.
. Eckert).
ll rights reserved.sequential proteolytic cleavage by different secretases. There are two
concurrent cleavage pathways. In the non-amyloidogenic pathway,
APP is ﬁrst cleaved at the N-terminus by α-secretase within the Aβ
sequence and precludes the formation of Aβ. α-Secretase is a member
of the ADAM (a disintegrin and metalloprotease) family [8]. Via their
metalloprotease domain, ADAMs are often implicated in ectodomain
shedding, either to release e.g. growth factors or to initiate further
intracellular signaling via regulated intramembrane proteolysis.
ADAMs 9, 10 and 17, have been proposed to act as α-secretases for
APP [9]. Proteolytic cleavage of APP by ADAM-enzymes produces a
105–125 kDa soluble N-terminal APP fragment (sAPPα) and an 83
residue membrane-associated C-terminal fragment (C83). The
secreted sAPPα exert anti-apoptotic and neuroprotective effects
[10]. Alternatively, Aβ is producedprimarily in the trans-Golgi network
and recycling compartments [11–14]. This amyloidogenic pathway
involvesﬁrst APP cleavage at theN-terminus byβ-secretase to produce
sAPPβ and a 99-residue membrane associated C-terminal fragment
C99. β-Secretase is a membrane-anchored aspartyl protease with its
active site in its ectodo-main and it was shown to be a member of the
memapsin family. Subsequent cleavage of C99 byγ-secretase produces
Alzheimer's amyloid β-protein precursor (APP) generate intracellular
domain fragment (AICD) along with varying lengths of extracellular
Aβ, the most common being Aβ(1–40) and Aβ(1–42). This model of Aβ
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contribution of both intracellular and extra-cellular Aβ is still an issue
of great controversy and interest in the ﬁeld [15].
APP processing by α-, β-, and γ-secretase, which are strictly
associated with cellular membranes, strongly depends on membrane
ﬂuidity. Modulation of membrane ﬂuidity for example affects the
accessibility of secretases acting on APP [16]. Kojro et al. showed that
α-secretase activity increased with enhanced membrane ﬂuidity [17].
Decreased membrane ﬂuidity augments γ-secretase activity [18].
Moreover, processing of APP by β-secretase also might be explained
by alterations in cell membrane ﬂuidity [19].
Membrane ﬂuidity may contribute to the processing of APP and the
cleavage product Aβmay in turn perturb the membrane environment.
Studies have examined the effects of Aβ peptides onmembraneﬂuidity
in model membranes and biological membranes of mice, rats and
humans (summarized in [20]). It is well recognized that changes in the
physico-chemical state of the membrane can markedly alter activity of
various membrane proteins, including α-, β-, and γ-secretase. The cell
membrane represents the ﬁrst site of interaction between Aβ and
neurons, andmay be the locationwhere the neurotoxic cascade of Aβ is
initiated. Themechanism bywhich Aβ affects membrane ﬂuidity is not
well-understood. Yanagiswa et al. discovered that Aβ binds to
monosialoganglioside (GM-1 ganglioside) and induces the assembly
of Aβ in the brain and in vitro [21]. GM-1 ganglioside reduces
membrane ﬂuidity of PC12 cells and alters the localization of receptors
within the plasma membrane [43]. We examined the hypothesis that
Aβ triggers the amyloidogenic processing of APP by decreasing
membrane ﬂuidity, which in turn stimulates its own production. Aβ
perturbation of the membrane may involve complexing with GM-1
ganglioside.
2. Materials and methods
2.1. Materials
Unless otherwise stated, all cell culture reagents were obtained
from Gibco/Invitrogen. The inhibitors and substances applied were
human Aβ(1–40) and rodent Aβ(1–42) (Bachem, Heidelberg, Germany),
Pluronic F68 (Sigma-Aldrich, Taufkirchen, Germany), Benzyl alcohol
(Fluka, Neu-Ulm, Germany), lovastatin (MSD Sharp and Dohme, Haar,
Germany) and DAPT (Sigma-Aldrich, Taufkirchen, Germany). The
Western blot reagents and Cholera Toxin Subunit B were obtained
from Invitrogen (Karlsruhe, Germany); the PVDF membranes, ECL
detection kit and hyper ﬁlms were obtained from GE Healthcare
(München, Germany). Trimethylamimmoniumdiphenylhexatrien
(TMA-DPH), 1,1,1,3,3,3- and hexaﬂuoro-2-propanol (HFIIP) were
obtained from Sigma-Aldrich (Taufkirchen, Germany).
2.1.1. Antibodies
Full length APP and C-terminal fragments (CTF) were detected
using mouse IgG C1/6.1 (kindly provided by Dr. Paul M. Mathews,
Nathan Kline Institute, Orangeburg, NY, USA) which was raised
against the conserved carboxyl-terminal 20 residues of APP (residues
676–695 of APP695)[22]. The secreted sAPPα was detected using
monoclonal mouse IgG 6E10 (Signet Laboratories, Cat.9320-02),
which recognizes the residues 1–17 of Aβ. Mouse anti-GAPDH was
obtained from Chemicon, Hofheim, Germany (Cat.MAB374). Anti-
mouse HRP-conjugated secondary antibody was purchased from
Calbiochem (Bad-Soden, Germany; (CAT.401253).
2.2. Cell culture
HEK293-cells and neuroblastoma SH-SY5Y-cells stable transfected
with human APP695 were cultured in Dulbecco's modiﬁed Eagle's
medium (DMEM) at 37 °C and 5% CO2. The HEK-medium was
supplemented with 10% FCS and penicillin/streptomycin. Geniticin(G418) was added at 3 μg/ml as a selective antibiotic. For incubation
with lovastatin, cells were grown in DMEM medium supplemented
with 2% v/v Ultroser G instead of FCS. Ultroser G is free of cholesterol,
requiring the cells to rely upon their ownde-novo synthesis. Cellswere
treated for 24 h with 1, 2 or 4 μM) lovastatin. Untransfected HEK293-
cells were cultured in the same medium without G418. Antibiotic
treatments per se had no impact on the effects reported (data not
shown). Medium for SH-SY5Y-APP695 cells was supplemented with
1% of glutamine, MEM-vitamins, Hygromycin B (3 μg/ml), pyruvate
and non-essential amino-acids plus 10% FCS. For lovastatin treatment,
cells weremaintained in serum-free OptiMEMmedium supplemented
withHygromycin B. The cellswere treated for 24hwith lovastatin (1, 2,
or 4 μM), Pluronic F68 (4.5 or 7.5 μM) and benzyl alcohol (5 or 10mM).
DAPT [1 μM]was added to the culture medium for at least 10 passages.
2.3. Preparation of Aβ(1–40) peptides
The preparation of monomeric, oligomeric and ﬁbrilar Aβ(1–40)
was performed as previously reported [23,24]. Brieﬂy, 1 mg of Aβ(1–40)
was dissolved in 200 μl 1,1,1,3,3,3-hexaﬂuoro-2-propanol and the
peptide solution was evaporated using a speed vacuum for 45 min.
2.3.1. Preparation of monomeric Aβ(1–40) peptides
The dried ﬁlmwas re-suspended in 2 μl DMSO and diluted in 98 μl
DMEMmedium to achieve a working solution of 100 μM. The solution
was vortexed for 30 s and immediately used for the experiments.
2.3.2. Preparation of oligomeric Aβ(1–40) peptides
The dried ﬁlmwas re-suspended in 2 μl DMSO and diluted in 98 μl
DMEMmedium to achieve a working solution of 100 μM. The solution
was vortexed for 30 s and incubated at 4 °C for 24 h.
2.3.3. Preparation of ﬁbrillar Aβ(1–40) peptides
The dried ﬁlmwas re-suspended in 2 μl DMSO and diluted in 98 μl
HCl 0,01 N to achieve a working solution of 100 μM. The solution was
vortexed for 30 s and incubated at 37 °C for 24 h. Aβ(1–40) peptides
were characterized using native gel electrophoresis, followed by silver
staining and electron microscopy as described below.
2.4. Characterization of Aβ(1–40) peptides
Blue native SDS-PAGE gel electrophoresis and silver staining was
performed according procedures previously published [25]. Prepared
Aβ(1–40) samples (see above) were mixed with 6× Laemmli buffer in a
sample/buffer ratio of 5:1 (Boston bioproduct, Cat # ADP-111R) and
placed in wells of 13% polyacrylamide gel (0.75 mm). The gel was run
in a 1× trisglycerine-SDS buffer from Bio-Rad at a constant voltage
(90 mV for 10 min then at 180 mV for another 60 min). Finally, the gel
was silver stained (Silver Stain Plus Kit from Bio-Rad (cat # 161-0449)
according to the manufacturer's instructions.
Transmission electron microscopy was used for visualization of Aβ
peptides as previously described [26]. Aliquots of Aβ(1–40) samples
(10 μl) were pipetted on to the surface of coated copper microscope
grids. The grids were air-dried and the samples were then stained
with 1% uranyl acetate. Grids were examined in an electron
microscope (EM 109, Zeiss, Oberkochen, Germany).
2.5. Western blot analysis
Total protein levels were determined by the Lowry method. The
samples were prepared by diluting 20 μg protein with the reducing
agent (10×) and loading buffer (4×). After denaturation for 10 min at
90 °C, the samples were electrophoresed on a 4–12% NuPage Bis/Tris
gel for 40 min at 200V and then transferred on a PVDF membrane for
90 min at 30 V. For the detection of secreted sAPPα, the conditioned
medium was collected and the values were normalized to the cell
Fig. 1. Effects of oligoAβ(1–40) on membrane properties and the processing of APP;
HEK293-APP695 cells were incubated for 24 h in the presence or absence of 1 μM
oligoAβ(1–40); (A) Changes in the membrane ﬂuidity, which is inversely correlated to
the anisotropy of the ﬂuorescence probe TMA-DPH, were determined using ﬂuores-
cence polarization spectroscopy in living cells; (B) Levels of endogenous Aβ(1–42) were
determined by ELISA [pg/mg protein]; (C) Representative Western blot analysis of full-
length APP and its fragments: The supernatants and cells were collected after
incubation; proteins were separated by gel electrophoresis and transferred to PVDF
membranes; secreted sAPPαwas detected in cell supernatants using antibody 6E10; for
APP and CTF analyses, cell homogenates were probed with the antibody C1/6.1; GAPDH
served as loading control; Data are means±SD n=6–9 (⁎pb0.05; ⁎⁎⁎pb0.001).
966 I. Peters et al. / Biochimica et Biophysica Acta 1788 (2009) 964–972lysate protein concentration. The membranes were blocked overnight
and incubated with the primary antibody for 1 h. After washing, the
blot was hybridized with an HRP-conjugated secondary antibody for
30 min. Visualization was done using an ECL detection kit from GE
Healthcare. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
served as a loading control. Band analysis was performed using
BioRad's Quantity One software.
2.6. ELISA detection of Aβ(1–42) and sAPPα
The Aβ(1–42) levels were determined using ELISA-kits from
Biosource, Solingen, Germany (Cat.KHB3482 and KHB3544) according
to the manufacturer's instructions. Brieﬂy, the conditioned medium
was collected and supplemented with PMSF. The cells were collected
andwashed twicewith 1× PBS. After centrifugation (22,000×rpm, 2 h,
4 °C), the cells were resuspended in guanidine hydrochloride (HCL,
5M) and incubated for 4 h. The suspensionwas diluted and centrifuged
at 16,000 ×g for 20 min. The supernatant was used for the ELISA.
In those experiments where oligoAβ(1–40) was added to cells,
cellular Aβ(1–40) levels could not be determined in parallel, since the
antibody used in the ELISA-kit for Aβ(1–40) detects both, cellular
endogenous and added exogenous Aβ(1–40) (data not shown).
For the quantitative analysis of sAPPα, wild type APP over-
expressing HEK and control cells were plated at equal density in 24
well plates. Conditioned, serum-free media were collected after 24 h
and supernatants were centrifuged at 200 ×g for 4 min to eliminate
cell debris. Soluble sAPPα was quantiﬁed using the IBL human sAPPα
colorimetric sandwich ELISA Kit (IBL Immuno-Biological Laboratories,
Hamburg, Germany) according to the supplier's instructions.
2.7. Determination of membrane ﬂuidity in living cells
The membrane ﬂuidity of living cells was determined as earlier
described [28]. The ﬂuorescence polarization probe TMA-DPH
incorporates very rapidly into plasma membranes of cells, and is
speciﬁcally localized on the cell surface making its use particularly
appropriate for determining plasma membrane ﬂuidity in living cells.
Cells were washed twice with warm HBSS and supplemented with
2 μM TMA-DPH. 700,000 cells per vial were incubated at 37 °C for
20 min. The membrane ﬂuorescence polarization was determined
using a SLM Aminco Bowman Series 2 luminescence spectrometer.
The cuvette temperature was 37 °C. The steady-state ﬂuorescence
polarization (Ps) was expressed as the anisotropy (rs) of the probe,
using the following equation: rS=2Ps/3−Ps. The rs is inversely
correlated to the membrane ﬂuidity, particularly to the acyl-chain
ﬂexibility of phospholipids.
2.8. Fluorescence and laser scanning ﬂuorescence microscopy
Aβ was stained using Fluoro-Aβ(1–40) conjugated with Fluorescein
(Advanced Bioconcept, Cat. AB2012). GM-1 gangliosidewas visualized
using ﬂuorescent labeled cholera toxin subunit B. Brieﬂy,100,000 cells
were plated overnight on cover slips coated with polylysin. Next, the
mediumwas supplementedwith 2 μMoligoAβ(1–40) containing 25 nM
of Fluoro-Aβ(1–40) for 24 h. After incubation, 2 μl of cholera toxin
subunit B conjugated with Alexa Fluor 555 were added to the culture
medium, which was then incubated for 10 min. The cells were washed
three times with PBS and incubated with 1.990 ml medium plus 10 μl
of the anti-cholera toxin antibody (Calbiochem, Darmstadt, Germany;
Cat. 227040) for 15min. Again, the cells werewashed three timeswith
PBS and ﬁxed with 4% paraformaldehyde for 30 min at 4 °C.
Cholesterol was stained in ﬁxed cells using ﬁlipin (50 μg/ml in PBS)
(Sigma-Aldrich, Taufkirchen, Germany; Cat. F9765).
For ﬂuorescence microscopy, Gel Mount was used to ﬁx the object
slide. The ﬂuorescent images were acquired on a Nikon ECLIPSE E800
microscope equipped with a Nikon DXM1200C digital cameraconnected to a PC. The images were evaluated using the Nikon NIS-
Elements Imaging software package.
For confocal laser-scanning ﬂuorescence microscopy, the samples
were embedded in Mowiol and analyzed using a confocal laser-
scanning microscope (Leica TCS SP5, Wetzlar, Germany), equipped
with a 63×1.4 oil-immersion objective. The images were evaluated
using the Imaris Imaging and Imaris Coloc Software (Version 6.2.0).
2.9. Determination of unesteriﬁed cholesterol
Unesterﬁed cholesterol levels were determined using the CHOD-
PAP method (Cholesteroloxidase-Peroxidase-Aminophenazon-Phe-
nol) developed in our lab as reported earlier [29]. Cellswere centrifuged
Fig. 2. Effects of endogenous Aβ levels on membrane ﬂuidity; (A) Aβ levels were
determined by ELISA [pg/mg protein] in HEK293 cells, either transfected with human
APP695 (HEK–APP) or human APP695 harboring the Swedish mutation (HEK–APPsw)
and in control cells (HEK); (B) Changes in the membrane ﬂuidity, which is inversely
correlated to the anisotropy of the ﬂuorescence probe TMA-DPH,were determined using
ﬂuorescence polarization spectroscopy in living cells; Data are means±SD; n=6–9
(⁎⁎⁎pb0.001).
Fig. 3. Effects of the γ-secretase inhibitor DAPT on the Aβ production and membrane
ﬂuidity; HEK293-AβPP695 cells were treated with 1 μM DAPT for at least 10 passages;
(A) Changes of cellular Aβ(1–42)-levels were determined using ELISA at the end of the
incubation period [pg/mg protein]; (B) Changes of the membrane ﬂuidity in living cells
were measured using TMA-DPH anisotropy as described in the Materials and methods;
(C) APP processing fragments were analyzed by Western blot analysis (please refer to
Fig. 1). Data are means±SD; n=6–9 (⁎⁎⁎pb0.001).
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with a protease-inhibitor cocktail (Roche) and frozen at−80 °C. Before
use, the cells were homogenized using a Dounce homogenizer ﬁtted
with a Teﬂon pestle and a Brandson sonicator.
2.10. Cytotoxicity
The cytotoxicity of Aβ, benzyl alcohol, pluronic F68 and lovastatin
used in the current study was determined using the MTT assay as
previously reported [30]. No cytotoxicity was observed for the
concentrations of inhibitors and substances used in the current
study (data not shown).
2.11. Statistics
All experiments were done at least in three independent experi-
ments and all assays were done in triplicates. Statistical analyses were
performed using one-way ANOVA followed by a Tukey comparison
test. All data were expressed as the means±SD. The correlations were
calculated using the Pearson using GraphPad Prism 4.0 software
package (San Diego, USA).
3. Results
3.1. Oligomeric Aβ(1–40) reduces membrane ﬂuidity and enhances
β-secretase cleavage of APP
Aβ interacts with neuronal membranes and decreases ﬂuidity [20].
We tested if Aβ induced changes inmembraneﬂuidity alters processingof APP in living cells. Cells stably transfected with human APP695 were
incubated with oligomeric Aβ(1–40) (oligoAβ(1–40)). Then ﬂuorescence
polarization of TMA-DPH, Aβ(1–42) levels, C-terminal fragments of APP
(CTF) and sAPPα levels were determined. Transfecting the APP gene
induces an overproduction of the protein, and APP overproduction
increases Aβ peptide secretion [31]. In the following experiments non-
neuronal humanembryonic kidney cells stably transfectedwith human
APP695 (HEK293–APP695) were used, which provides expression
levels that are sufﬁcient for adequate assessment of APP cleavage
products, such as sAPPα (Supplementary Fig. 3).
Treatment with oligoAβ(1–40) signiﬁcantly decreased plasma
membrane ﬂuidity of living cells (Fig. 1A) and increased levels of
secreted cellular Aβ(1–42) (Fig. 1B). Western blot analysis revealed that
the levels of C99, the β-secretase related C-terminal fragment (CTF),
are signiﬁcantly elevated by oligoAβ(1–40) (Fig. 1C). α-Secretase
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unchanged.
To assess the inﬂuence of peptide aggregation on the membrane
ﬂuidity of living cells and the production of Aβ(1–42), we compared the
effects of monomeric, oligomeric and ﬁbrillar Aβ(1–40), which were
characterized by native gel electrophoresis and electron microscopy
(Supplementary Fig. 1). Monomeric Aβ(1–40) has no effect on
membrane ﬂuidity and Aβ(1–42) production (Supplementary Fig. 2).
Effects of oligoAβ(1–40) on membrane ﬂuidity and on production of
Aβ(1–42) were much more pronounced compared to ﬁbrillar Aβ(1–40)
(Supplementary Fig. 2).Fig. 4. Impact ofmembraneﬂuidity on the cleavage of APP; (A–C)HEK293-APP695 cellswere t
were determined using ELISA [pg/mg protein]; (A, D) Changes in the membrane ﬂuidity were
analyzed byWestern blot analysis; the secreted sAPPαwas detected in themediumusing the a
detected with the antibody C1/6.1; GAPDH served as loading control; Band analysis was perfo
⁎⁎⁎pb0.001).3.2. Cellular Aβ levels determine membrane ﬂuidity of living cells
We next investigated, if endogenous Aβ produced by cells
harboring the human APP695 protein was associated with membrane
ﬂuidity of living cells. A majority of the mutations in human APP that
have been tested, when transfected in cellular models, induce an
increase in Aβ(1–40) and Aβ(1–42) levels [31]. Therefore, we examined
ﬂuidity in cells, expressing human APP695 (HEK–APP) and human
APP695 harboring the Swedish mutation (HEK–APPsw). Expression of
human APP is related to enhanced levels of Aβ (Fig. 2A). Cells
expressing human APP harboring the Swedish mutation releasedreatedwith benzyl alcohol or (D–F) Pluronic F68; (B, E) The levels of endogenous Aβ(1–42)
measured as described in the Materials and methods (C, F) APP cleavage products were
ntibody 6E10; full-length APP and its C-terminal fragments in the cell homogenateswere
rmed using BioRad's Quantity One; Data are means±SD; n=6–12 (⁎pb0.05; ⁎⁎pb0.01;
Fig. 5. Binding of Aβ to GM–1 ganglioside; confocal laser-scanning ﬂuorescence microscopy was used to visualize the cellular localization of Aβ and GM-1 ganglioside. (A–D)
Representative images of the HEK293-APP695 cells; Fluoro-oligoAβ(1–40) was added to the medium and cells were stained for (A) cholesterol using ﬁlipin, (B) GM-1 ganglioside
using Alexa 555-conjugated cholera toxin subunit B (CTX-Aexa555) and for (C) Aβ using Fluoro-oligoAβ(1–40). (D) Merged pictures reveal that oligoAβ(1–40) attaches to the cell
membrane (Scale bar=7.5 μm). Co-localization of oligoAβ(1–40) and GM-1 was described by the presence of the two ﬂuorochromes at the same physical location. (E) The 2D-
histogram displays the degree of overlap of the green (Fluor-oligoAβ(1–40)) and red (CTX-Alexa555) ﬂuorescence and reﬂects the distribution of pairs of voxel intensities occurring in
the two selected channels. The range of intensity pairs considered as co-localized was deﬁned after deﬁnition of the region of interest on the 2D histogram, its (F) result is indicated as
yellow color in the picture detail.
Fig. 6. Impact of GM-1 ganglioside on the production of cellular Aβ; HEK293-APP695
cells were treated for 24 h with 1 μM Choleratoxin subunit B (CTX), which speciﬁcally
binds to GM-1 ganglioside. (A) Changes in the membrane ﬂuidity after incubation with
CTXweremeasured as described in the Materials andmethods (B) The levels of cellular
Aβ(1–42) after incubation CTX were determined using ELISA [pg/mg protein]; Data are
means±SD; n=6–12 (⁎⁎⁎pb0.001).
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were related to reduced membrane ﬂuidity (Fig. 2B), indicating that
endogenous Aβ perturbed the plasma membrane.
Incubation of HEK–APP cells with the γ-secretase inhibitor DAPT
abolished production of endogenous Aβ(1–42) (Fig. 3A) and normal-
ized membrane ﬂuidity in HEK293–APP695 cells (Fig. 3B). These
results indicate that the observed changes in membrane ﬂuidity were
due to the endogenous production of Aβ.
3.3. Membrane ﬂuidity determines the processing of APP
To conﬁrm that oligoAβ(1–40) stimulated β- and γ-secretase
cleavage of APP by altering membrane ﬂuidity (Fig. 1), we used
compounds that increase (benzyl alcohol) or decrease membrane
ﬂuidity (Pluronic F68; PF68) [32,33]. Treatment with benzyl
alcohol increased membrane ﬂuidity (Fig. 4A) and reduced cellular
Aβ(1–42) levels in HEK293–APP cells (Fig. 4B). Elevated sAPPα
levels induced by benzyl alcohol were associated with reduced CTF
C99 levels and elevated CTF C83 levels (Fig. 4C), indicating
enhanced α-secretase cleavage of APP. Pluronic PF68 reduced
membrane ﬂuidity (Fig. 4D) and increased levels of endogenous
Aβ(1–42) (Fig. 4E). Secretion of sAPPα in living HEK293–APP695
cells was reduced (Fig. 4F). CTF C99 levels were increased and CTF
C83 were decreased after PF68 treatment, indicating enhanced β-
secretase cleavage of APP (Fig. 4F).
We also used lovastatin, which increases membrane ﬂuidity by
lowering cholesterol levels, and has been shown to stimulate α-
secretase-related processing of APP and reducing Aβ production in
cells [17,34,35]. We conﬁrmed that lovastatin reduced both cellular
cholesterol and Aβ(1–42) levels and increased secreted levels of sAPPα
and membrane ﬂuidity. β-secretase-related CTF C99 was signiﬁcantly
reduced (data not shown). In contrast to lovastatin, benzyl alcohol and
Pluronic F68 did not alter membrane cholesterol levels (data not
shown), suggesting that the observed effects of membrane ﬂuidity on
APP processing were cholesterol independent.
970 I. Peters et al. / Biochimica et Biophysica Acta 1788 (2009) 964–9723.4. OligoAβ(1–40) binds to GM-1 ganglioside in living cells
Aβ binds to membrane-bound GM-1 ganglioside and it has been
proposed that this binding acts as an endogenous seed for amyloid
ﬁbrillization [21]. To test whether the oligoAβ(1–40) induced reduction
of membrane ﬂuidity in HEK293-APP695 cells (Fig. 1B) involves GM-1
ganglioside, we incubated cells with ﬂuorescein-labeled oligoAβ(1–40)
(ﬂuoro-oligoAβ(1–40)). The cells were also stained for GM-1 ganglio-
side using Alexa555-labelled cholera toxin subunit B and cholesterol
using ﬁlipin (Fig. 5). Blue ﬂuorescence of ﬁlipin indicated plasma
membrane bound cholesterol (Fig. 5). Confocal laser scanning
ﬂuorescence microscopy revealed co-localization of Alexa555-
labelled cholera toxin subunit B and ﬂuoro-oligoAβ(1–40), which was
indicative of oligoAβ(1–40) binding to GM-1 ganglioside (Fig. 5).Fig. 7. Membrane ﬂuidity and cleavage of APP in neuronal cells. SH-SY5Y-APP695 cells
were treated as described inMaterials andmethods; (A)Membraneﬂuidity of living cells
was correlated to endogenous Aβ(1–40) levels [pg/mg protein]; cells were treated for 24 h
with lovastatin (1, 2 and 4 μM), Benzyl alcohol (5 and 10 mM) and Pluronic F68 (4.5 and
7.5 μM); (B–D) Representative ﬂuorescencemicroscopy images of the SH-SY5Y-AβPP695
cells; (B) Fluoro-oligoAβ(1–40) was added to the medium and cells were incubated for
24 h; (C) Cells were stained for GM-1 ganglioside using Alexa 555-conjugated cholera
toxin subunit B; (D) Co-localization of Fluoro-oligoAβ(1–40) and Alexa 555-conjugated
cholera toxin sub-unit B. Data are means±SD; n=6–12.3.5. Choleratoxin reduces membrane ﬂuidity and enhances cellular Aβ
production
If GM-1 ganglioside contributes to the oligoAβ(1–40) induced
reduction of membrane ﬂuidity and altered processing of APP, then
binding of GM-1 ganglioside to other compounds shouldmimic effects
of Aβ. HEK293-APP695 cells were incubated with choleratoxin
subunit B (CTX), which speciﬁcally binds to its cell surface receptor
GM-1 [36] and it was determined if CTX also reduces membrane
ﬂuidity and increases endogenous Aβ levels in cells. Binding of CTX to
GM-1 ganglioside signiﬁcantly reduced membrane ﬂuidity and
increased cellular Aβ(1–42) levels (Fig. 6A and B) ﬁndings, which
were similar to effects of oligoAβ(1–40) as described above. These
ﬁndings suggest that GM-1 gangliosides play a role in Aβ effects on
membrane ﬂuidity and APP cleavage.
In order to investigate possible effects of Aβ on its own
production, we studied the inﬂuence of oligoAβ(1–40) on the release
of cellular Aβ(1–42) in HEK293-APP695 cells. Aβ(1–42) could be
determined by a speciﬁc and very sensitive ELISA. In order to prove
that Aβ also regulates ectodomain shedding of APP in neuronal cells,
we used the SH-SY5Y cell line.
Again, a very good correlation was found between membrane
ﬂuidity (modulated by Pluronic F68, benzyl alcohol and lovastatin)
and cellular Aβ(1–40) production (Fig. 7A). OligoAβ(1–40) modulation of
Aβ(1–42) release could not be investigated, since levels of Aβ(1–42) were
below the detection limit.
SH-SY5Y-APP695 cellswere also incubatedwith ﬂuoro-oligoAβ(1–40)
(Fig. 7B) and stained for GM-1 ganglioside using Alexa555-labelled
cholera toxin subunit B (Fig. 7C). Co-localization of Alexa555-labeled
cholera toxin subunit B and ﬂuoro-oligoAβ(1–40) is indicative of
oligoAβ(1–40) binding to GM-1 ganglioside (Fig. 7D), also in neuronal
cells.
In summary, manipulation of the membrane ﬂuidity using
different compounds also modulates cellular Aβ levels and oligoAβ(1–
40) binds to GM-1 ganglioside in SH-SY5Y-APP695 cells, indicating
that theses data are conﬁrmatory of the ﬁndings we obtained using
non-neuronal cells.
4. Discussion
There is evidence that the membrane lipid environment modulates
secretase activity and potentially affects the function and conformation
of the enzymes, inﬂuencing substrate selection and the distribution of
APP cleavage sites [37]. In the present studywe showed that Aβ triggers
the amyloidogenic processing of APP by decreasing membrane ﬂuidity
and stimulated its own production in living cells. The Aβ perturbation
of the membrane was associated with Aβ complexing with GM-1
ganglioside. Our data showed that inhibition of γ-secretase inhibited
Aβ production, increased membrane ﬂuidity and stimulated α-
secretase cleavage of APP in APP695 over-expressing cells underlines
this notion. In vivo support for the potential importance of membrane
ﬂuidity in APP processing are reports that the polyunsaturated fatty
acid docosahexaenoic acid enhanced synaptic membrane ﬂuidity in
aged mice [38] and decreased Aβ levels in brains of murine ADmodels
[39, 40].
The Aβ-induced reduction in ﬂuidity may involve GM-1 ganglio-
side. This idea is based on several different lines of evidence. The cell
surface association of ﬂuoro-oligoAβ(1–40) with GM-1-gangliosidewas
observed in plasma membranes of intact cells, which conﬁrms GM-1
ganglioside as a potential target molecule of Aβ in plasmamembranes
[21]. These results are in agreement with recent ﬁndings showing that
GM-1 ganglioside induces Aβ assembly on the cell surface [41].
Binding of oligoAβ to GM-1 ganglioside may induce changes in
membrane ﬂuidity, which in turn provides an energy favorable
environment for β- and γ-secretase within the plasma membrane.
GM-1 ganglioside regulates membrane structure, increases the order
971I. Peters et al. / Biochimica et Biophysica Acta 1788 (2009) 964–972of hydrocarbon chains and decreases ﬂuidity in sphingolipid-enriched
membranes [42]. GM-1 ganglioside reduces the membrane ﬂuidity of
PC12 cells and alters the localization of receptors within the plasma
membrane [43]. Binding of cholera toxin protein to membrane-
incorporated GM-1 ganglioside alters the long-range lateral diffusion
of ﬂuorescently labeled lipids [44]. Importantly, we demonstrate that
binding of cholera toxin to GM-1 reduces membrane ﬂuidity and
enhances the production of cellular Aβ(1–42), which are similar to
effects of oligoAβ(1–40). Moreover, previous reports show that GM-1
ganglioside regulates APP cleavage [45–47]. These ﬁndings further
support the notion that Aβ affects the processing of APP in part by
binding to GM-1. While Aβ targeting of GM-1 ganglioside may reduce
ﬂuidity, it is worth noting that we have been reported previously that
aggregated Aβ has a high binding afﬁnity for cholesterol as compared
with phosphatidylcholine and saturated fatty acids [25]. It is well-
established that membrane ﬂuidity is reduced when cholesterol levels
are increased and that APP processing is inﬂuenced by cholesterol
abundance [17,34,35]. However, our ﬁndings with lovastatin indicate
thatmembrane ﬂuidity determines the processing of APP independent
of cholesterol levels.
Sporadic AD is related to advancing age far more than any other
risk factor and there is evidence that sporadic AD overlaps with
normal aging inmany clinical and pathologic features [27,48]. Changes
inmembrane properties are distinguishingmarkers of brain aging [49,
50]. In particular, membrane ﬂuidity is less in synaptosomal plasma
membranes isolated from brains of aged versus young mice [29].
Hippocampal membranes, isolated from brains of AD patients were
signiﬁcantly less ﬂuid compared to membranes of age-matched
controls [51]. Thus, age-related reduction of synaptosomal membrane
ﬂuidity may provide the optimal environment for β- and γ-secretase
cleavage of APP.
Based on our novel ﬁndings, we propose that oligoAβ interacts
with neuronal membranes by decreasing membrane ﬂuidity and
binding to GM-1 ganglioside, which accelerates the proteolytic
cleavage of APP and starting a vicious circle in which endogenous
Aβ stimulates its own production. This process may be further
enhanced by reduced membrane ﬂuidity which occurs during brain
aging.
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